Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Harvoni Cost Will Be Roughly Equal To Sovaldi For Most HCV Patients (Updated)

This article was originally published in The Pink Sheet Daily

Executive Summary

Sovaldi/ledipasvir combo pill – the first one-tablet, oral hepatitis C option in the U.S. – was approved Oct. 10 with a price of $94,500 for a 12-week course of therapy, similar to the cost of Sovaldi plus interferon and ribavirin. Insurers group says Gilead “seems to believe it has a blank check.”


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts